Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The pathogenesis of allergic conjunctivitis.

A Keane-Myers1

  • 1Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Twinbrook II Facility, Room 200E, 12441 Parklawn Drive, Rockville, MD 20852, USA. akeane@niaid.nih.gov

Current Allergy and Asthma Reports
|March 15, 2002
PubMed
Summary

Allergic conjunctivitis symptoms range widely, and current treatments offer only temporary relief by managing mast cell degranulation. Further research into allergic eye disease models is crucial for developing effective, long-term anti-allergic therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of a biodegradable microparticulate polymer as a carrier for Burkholderia pseudomallei subunit vaccines in a mouse model of melioidosis.

International journal of pharmaceutics·2015
Same author

The architectural transcription factor high mobility group I(Y) participates in photoreceptor-specific gene expression.

The Journal of neuroscience : the official journal of the Society for Neuroscience·2000
Same author

Molecular and cellular aspects of allergic conjunctivitis.

Chemical immunology·1999
Same author

Resistance to antigen-induced airway hyperresponsiveness requires endogenous production of IL-12.

Journal of immunology (Baltimore, Md. : 1950)·1998
Same author

Molecular basis and role of differential cytokine production in T helper cell subsets in immunologic disease.

Advances in experimental medicine and biology·1998
Same author

B7-CD28/CTLA-4 costimulatory pathways are required for the development of T helper cell 2-mediated allergic airway responses to inhaled antigens.

Journal of immunology (Baltimore, Md. : 1950)·1997

Area of Science:

  • Ophthalmology
  • Immunology
  • Allergy

Background:

  • Allergic conjunctivitis presents with diverse clinical manifestations, from mild discomfort to severe, vision-threatening conditions.
  • The underlying pathophysiology involves complex immune responses, including IgE-mediated hypersensitivity and mast cell degranulation, but remains incompletely understood.
  • Current treatments often provide only palliative relief, failing to address the root immune mechanisms, leading to symptom recurrence upon discontinuation.

Purpose of the Study:

  • To explore the complex pathophysiology of allergic conjunctivitis.
  • To highlight the limitations of current palliative treatments.
  • To emphasize the importance of disease models in discovering novel therapeutic agents.

Main Methods:

  • Review of clinical presentations and known immunological mechanisms of allergic conjunctivitis.

Related Experiment Videos

  • Analysis of the biochemical pathways involved in mast cell degranulation and mediator release.
  • Evaluation of the role of animal and in vitro models in preclinical research for allergic eye diseases.

    • Main Results:

    • Clinical presentations of allergic conjunctivitis exhibit significant variability.
    • Mast cell degranulation and subsequent mediator release are central to allergic eye symptoms.
    • Existing therapies are largely palliative, necessitating continuous application for symptom control.

    Conclusions:

    • The pathophysiology of allergic conjunctivitis is complex, involving intricate immune reactions.
    • There is a need for treatments that target the underlying immune response rather than just symptoms.
    • Models of allergic eye disease are instrumental in the development of new anti-allergic and anti-inflammatory compounds for ocular use.